Delaying Treatment Has Consequences: The Case for Acting Quickly When Herpes Strikes

There is a moment that many people with herpes simplex virus know intimately — the first tingling sensation, the unfamiliar discomfort, the quiet dread of recognizing what is beginning. For some, that moment leads immediately to a phone call to a physician and a prompt prescription. For far too many others, it leads to waiting. Hoping the symptoms will resolve on their own. Avoiding a conversation that feels uncomfortable. Convincing themselves that treatment is unnecessary or that the infection is not serious enough to warrant medical attention.

That delay carries a cost. And the evidence suggests it is higher than most patients realize.

The Scale of the Problem in the United States

Herpes simplex virus is among the most prevalent viral infections in the United States. The Centers for Disease Control and Prevention estimates that approximately one in six Americans between the ages of 14 and 49 has genital herpes caused by HSV-2, and HSV-1 — the strain most commonly associated with oral herpes — infects an even larger proportion of the population. Despite these numbers, the majority of those infected are either unaware of their status or have never received antiviral treatment.

This is not primarily a failure of medicine. Effective, affordable antiviral therapy has existed for decades. Acyclovir, approved by the FDA in 1982, remains one of the most well-studied antiviral medications in clinical history. The barrier to treatment is not pharmaceutical — it is behavioral, psychological, and cultural.

Why People Wait — And Why That Logic Fails

The reasons patients delay seeking care are understandable, even if the consequences are not acceptable. Herpes carries a disproportionate social stigma that has little relationship to the actual medical severity of the infection for most healthy adults. That stigma discourages people from acknowledging symptoms, discussing the diagnosis with a partner, or walking into a clinic to request an evaluation.

Beyond stigma, there is a pervasive misconception that herpes is self-limiting and therefore untreatable in any meaningful sense. Many patients have been told — or have concluded on their own — that antivirals only shorten an outbreak by a day or two and are therefore not worth the effort of obtaining a prescription. This framing fundamentally misunderstands the cumulative and long-term value of antiviral therapy.

The reality is more nuanced and more urgent.

What Early Acyclovir Treatment Actually Accomplishes

When acyclovir is initiated at the earliest sign of an outbreak — ideally within 72 hours of symptom onset — the clinical benefits are well-documented and clinically meaningful.

For a first-episode genital herpes outbreak, early acyclovir therapy has been shown to reduce the duration of viral shedding by more than 50 percent, significantly shorten the healing time for lesions, and reduce the intensity of pain and discomfort. First episodes of genital herpes can be particularly severe, sometimes involving systemic symptoms such as fever, body aches, and swollen lymph nodes. Prompt antiviral treatment mitigates these effects in ways that watchful waiting simply cannot.

For recurrent outbreaks, episodic acyclovir therapy started at the prodromal stage — when patients experience tingling or burning before visible lesions appear — can in some cases abort the outbreak entirely, preventing lesion formation altogether. That outcome is not achievable once the infection has progressed.

For patients with frequent recurrences, daily suppressive therapy with acyclovir reduces outbreak frequency by approximately 70 to 80 percent in clinical studies. It also lowers the rate of asymptomatic viral shedding, which is the mechanism by which herpes is most commonly transmitted to sexual partners.

The Less-Discussed Risks of Untreated Infection

Shortened outbreaks and reduced transmission risk are compelling reasons to treat. But the argument for early acyclovir therapy extends beyond episodic symptom management.

Neurological involvement is a concern that rarely enters public discussion about herpes simplex virus, yet it is clinically significant. HSV-1 and HSV-2 establish latency in sensory nerve ganglia — clusters of nerve cells near the spinal cord and brain stem. The virus does not simply reside in skin cells between outbreaks; it lives in neural tissue. Repeated reactivations have been associated in some research with chronic nerve pain (post-herpetic neuralgia-like symptoms in HSV patients), and in immunocompromised individuals, untreated herpes can lead to encephalitis — a life-threatening inflammation of the brain.

While herpes encephalitis is rare in immunocompetent adults, the neurological dimension of this virus is a reminder that herpes is not merely a dermatological inconvenience. Acyclovir is, in fact, the standard of care for herpes simplex encephalitis when administered intravenously — a detail that underscores the seriousness with which the medical community views this pathogen.

Transmission to vulnerable populations represents another consequence of delayed or absent treatment. Neonatal herpes — transmitted from mother to infant during childbirth — is a serious and potentially fatal condition. Pregnant individuals with active or unrecognized herpes infection who do not receive appropriate antiviral management face elevated risks of transmission during delivery. Early identification and suppressive acyclovir therapy during the third trimester is a recognized strategy for reducing this risk.

Increased susceptibility to other infections is also relevant. Active herpes lesions disrupt the integrity of mucosal and skin barriers, creating entry points for other pathogens. Epidemiological data has long established a bidirectional relationship between HSV-2 infection and elevated risk of HIV acquisition, in part because of this mechanism. Managing herpes outbreaks effectively — through antiviral therapy — is therefore not only about comfort; it has broader implications for sexual health.

Confronting the Stigma That Prevents Care

Addressing the clinical case for early treatment without acknowledging the stigma that prevents it would be incomplete. In the United States, the cultural narrative around herpes has been shaped more by late-night television jokes and dating app anxiety than by public health education. That narrative has caused measurable harm.

Patients who feel shame about a herpes diagnosis are less likely to disclose to partners, less likely to seek medical care, and less likely to adhere to treatment when it is prescribed. This is not a character failing — it is a predictable response to an environment that has treated a common, manageable viral infection as a marker of moral failure rather than a medical condition.

Healthcare providers, patient advocates, and resources like this one have a responsibility to challenge that framing directly. Herpes simplex virus is a chronic but treatable infection. It does not define a person's worth, their relationships, or their future. What it does require is informed, timely medical management — the same approach we take to any other chronic viral condition.

The Practical Takeaway

If you recognize the early signs of a herpes outbreak, contact a healthcare provider promptly. Do not wait to see whether symptoms worsen. Do not postpone the conversation out of embarrassment. The window for maximum antiviral effectiveness is narrow — typically the first 24 to 72 hours — and it closes quickly.

Acyclovir has been proven safe and effective across more than four decades of clinical use. It is available as a generic medication at pharmacies across the country, and telehealth platforms now make obtaining a prescription more accessible than ever for patients who prefer to avoid an in-person visit.

The decision to treat early is not an overreaction. It is the medically sound, evidence-supported choice. The hidden cost of untreated herpes — in prolonged outbreaks, potential transmission, and long-term health implications — is far greater than the cost of a prescription filled promptly at the onset of symptoms. That is not an opinion. It is what the clinical record consistently shows.